Expression of MIR155HG, LOC283856, KIAA0125, and LOC100190986 as potential prognostic and predictive biomarkers for breast cancer

Sep 22, 2026

Upload by Liam

Accumulating evidence has pointed out that the altered expression of long non-coding RNAs (lncRNAs) is involved in the physiopathology of breast cancer, yet the mechanisms driving progression remain unclear. The study evaluates cDNA microarray data to assess SPARC-related transcriptomic changes in MCF7 cells before and after docetaxel. Differentially expressed lncRNAs were selected and integrated with in silico analysis to identify prognostic and predictive markers across intrinsic subtypes. A set of nine lncRNAs correlated with survival and recurrence-free and overall outcomes on KM Plotter, and in silico results suggested predictive utility for treatment response.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages11

Reading Time28 min

AccessFree to download

Abstract

Key words

Introduction

Abstract (study design context)

Brazilian Journal of Medical and Biological Research (2026) 59: e14805, [https://doi.org/10.1590/1414-431X2025e14805](https://doi.org/10.1590/1414-431X2025e14805) ISSN 1414-431X Research Article 1/11 Expression of MIR155HG, LOC283856, KIAA0125, and LOC100190986 as potential prognostic and predictive biomarkers for breast cancer A.C. Pavanelli1,2 00 , F. R. R. Mangone1,2 00 , [G.P. de](G.P. de) Jesus1 00 , and M.A. Nagai1,2,3 00 1Laboratório de Genética Molecular, Centro de Investigaão Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil 2Centro de Estudos e Tecnologias Convergentes para Oncologia de Precisão, Universidade de São Paulo, São Paulo, SP, Brasil 3Disciplina de Oncologia, Departamento de Radiologia e Oncologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil Abstract Accumulating evidence has pointed out that the altered expression of long non-coding RNAs (lncRNAs) is involved in thephysiopathology of breast cancer (BC) . However, the role of lncRNAs in BC progression remains poorly understood. Here, we evaluated cDNA microarray data from a previous study from our group to investigate the effects of SPARC expression on the transcriptome of MCF7 cells before and after treatment with docetaxel. We analyzed our gene expression data to identify differentially expressed long non-coding RNAs (DELncRNAs) . In combination with in silico analysis, we selected a group of DELncRNAs with potential prognostic and predictive value for BC patients with tumors of different intrinsic subtypes. Overall, we identiﬁed 260 DELncRNAs comparing MCF7 cells with different expressions of SPARC after docetaxel treatment. Nine DELncRNAs (LOC646762, FLJ13224, CASC2, LOC100130691, MGC12916, LOC100190986, LOC283856, KIAA0125, and MIR155HG) showed signiﬁcant associations with BC survival on the KM Plotter platform. Of these 9 DELncRNAs, MIR155HG, LOC283856, LOC100190986, and KIAA0125 were signiﬁcantly correlated with recurrence-free survival and overall survival rates of BC patients, suggesting they could help predict the outcome of BC patients as prognostic factors. Moreover, in silico analysis showed that these DELncRNAs were able to predict BC patients’ responses to different treatment protocols. Key words: Breast cancer; lncRNAs; Biomarker; Prognosis; MIR155HG Introduction Breast cancer (BC) ranks highest in incidence and mortality among cancers affecting women worldwide and is considered an important public health problem. In 2020, 2.3 million women were diagnosed with BC, and 685,000 deaths were reported worldwide (1) . BC has a diverse etiology and is classiﬁed into four main molecular subtypes: Luminal A, Luminal B, HER2-positive, and triple-negative (TN) . Luminal tumors are characterized by the presence of estrogen receptors (ER) and progesterone receptors (PR), along with the absence of the HER- 2 oncogene. Luminal B tumors may express PR at either high or low levels, and HER-2 can also be detected in some cases. Due to their hormone receptor-positive status, these tumors can beneﬁt from endocrine therapies, such as selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), and aromatase inhibitors (AIs) . Patients with HER-2-positive breast tumors may respond positively to treatment with monoclonal antibodies. In contrast, triple-negative tumors lack expression of the ER, PR, and HER-2 receptors. The conventional treatment approaches for these tumors typically includes chemotherapy and surgery. BC is a complex disease with variability in its molecular, pathological, and clinical course, and its response to treatment (2) . Despite advances in the molecular classiﬁcation of BC, new biomarkers are needed for prognosis and prediction of patients ’ responses to different therapeutic strategies. Evidence has indicated that long non-coding RNAs (lncRNAs) play critical

FAQs

Which long non-coding RNAs were identified as potential biomarkers in breast cancer?

Nine DELncRNAs, including MIR155HG, LOC283856, LOC100190986, and KIAA0125, showed significant associations with breast cancer survival. These were identified from comparisons of MCF7 cells with different SPARC expressions after docetaxel treatment.

How were prognostic and predictive values evaluated in the study?

Differentially expressed lncRNAs were selected from gene expression analyses and then combined with in silico analysis. Prognostic associations were assessed using the KM Plotter platform, and predictive capacity was explored through in silico approaches.

What treatment context was used to study gene expression changes?

The study used cDNA microarray data from experiments examining MCF7 cells treated with docetaxel. SPARC expression levels were used as the key condition to compare transcriptomic differences and derive DELncRNAs.

Sep 22, 2026

Upload by Liam